User login
Key clinical point: First-line therapy with biologics, including abatacept and certolizumab pegol but not tocilizumab, all in combination with methotrexate, was clinically superior to conventional therapy with bridging glucocorticoids in patients with moderate-to-severe early rheumatoid arthritis (RA).
Major finding: Compared with active conventional therapy, the Clinical Disease Activity Index-based remission rates at week 48 were significantly higher with abatacept (adjusted difference +20.1%; P < .001) and certolizumab pegol (adjusted difference +13.1%; P = .021) but not with tocilizumab, whereas the radiographic progression was low and lacked between-group differences.
Study details: Findings are from the NORD-STAR trial including 812 treatment-naive patients with moderate-to-severe early RA who were randomly assigned to receive methotrexate combined with active conventional therapy, certolizumab pegol, abatacept, or tocilizumab.
Disclosures: This study was funded by the Academy of Finland, Finska Läkaresällskapet, and other sources. Several authors declared chairing the committees of or receiving travel support, research grants, or fees for lectures, speaking, consultancy, advisory roles, or other services from various sources.
Source: Østergaard M et al, on behalf of the NORD-STAR study group. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023 (Jul 9). Doi: 10.1136/ard-2023-224116
Key clinical point: First-line therapy with biologics, including abatacept and certolizumab pegol but not tocilizumab, all in combination with methotrexate, was clinically superior to conventional therapy with bridging glucocorticoids in patients with moderate-to-severe early rheumatoid arthritis (RA).
Major finding: Compared with active conventional therapy, the Clinical Disease Activity Index-based remission rates at week 48 were significantly higher with abatacept (adjusted difference +20.1%; P < .001) and certolizumab pegol (adjusted difference +13.1%; P = .021) but not with tocilizumab, whereas the radiographic progression was low and lacked between-group differences.
Study details: Findings are from the NORD-STAR trial including 812 treatment-naive patients with moderate-to-severe early RA who were randomly assigned to receive methotrexate combined with active conventional therapy, certolizumab pegol, abatacept, or tocilizumab.
Disclosures: This study was funded by the Academy of Finland, Finska Läkaresällskapet, and other sources. Several authors declared chairing the committees of or receiving travel support, research grants, or fees for lectures, speaking, consultancy, advisory roles, or other services from various sources.
Source: Østergaard M et al, on behalf of the NORD-STAR study group. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023 (Jul 9). Doi: 10.1136/ard-2023-224116
Key clinical point: First-line therapy with biologics, including abatacept and certolizumab pegol but not tocilizumab, all in combination with methotrexate, was clinically superior to conventional therapy with bridging glucocorticoids in patients with moderate-to-severe early rheumatoid arthritis (RA).
Major finding: Compared with active conventional therapy, the Clinical Disease Activity Index-based remission rates at week 48 were significantly higher with abatacept (adjusted difference +20.1%; P < .001) and certolizumab pegol (adjusted difference +13.1%; P = .021) but not with tocilizumab, whereas the radiographic progression was low and lacked between-group differences.
Study details: Findings are from the NORD-STAR trial including 812 treatment-naive patients with moderate-to-severe early RA who were randomly assigned to receive methotrexate combined with active conventional therapy, certolizumab pegol, abatacept, or tocilizumab.
Disclosures: This study was funded by the Academy of Finland, Finska Läkaresällskapet, and other sources. Several authors declared chairing the committees of or receiving travel support, research grants, or fees for lectures, speaking, consultancy, advisory roles, or other services from various sources.
Source: Østergaard M et al, on behalf of the NORD-STAR study group. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023 (Jul 9). Doi: 10.1136/ard-2023-224116